Unspecified Adult Solid Tumor
9
0
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction